English

Tripep AB (publ.) —Year-end Report 2004

Report this content

· Tripep’s loss after tax for the full year 2004 was SEK -25.8 million (SEK -13.0 m). Research and development costs for the full year 2004 were SEK 12.2 million (SEK 12.4 m). SEK 14.8 m has been capitalised since the project alphaHGA entered its clinical phase. The company recorded no net sales during the period. Earnings per share for the full year were SEK –2.06 (SEK -1.00). · Tripep’s anti-HIV drug alphaHGA has now completed the safety and toxicology trials necessary for filing an application to conduct phase I/II clinical trials in humans. A microdosage study in healthy volunteers demonstrated that alphaHGA can be administered as an oral medicine with a twice-daily dosage. The preparation of the necessary documentation for the Thai regulatory authorities is now being finalised. · In December, VLP Biotech Inc., in which Tripep has a 30% holding, was able to report that the first version of a universal influenza vaccine protects mice against a lethal dose of influenza A virus. · Tripep received a US patent for a new indication of the antiviral substance ribavirine. · Pursuant to authorization from Tripep’s Annual General Meeting (AGM), the Board of Directors successfully concluded a private placement raising SEK 21.25 million for the company excluding transaction costs. · The Board has decided to put a parallel listing on the London Stock Exchange AIM (Alternative Investment Market) on hold at present. Remium Securities has been appointed as liquidity provider. · Mr. Johan Ihre left his position as CEO in June 2004. The company’s Head of Research Anders Vahlne, held this position until the present CEO, Jan Nilsson, took up his position on December 1 2004. · Thomas Lynch was co-opted to the Board of Directors in December 2004. For more information, please contact Jan Nilsson, Chief Executive Officer Tel: +46 (0)8 449 84 82, mobile: +46 (0)70 466 31 63 e-mail: jan.nilsson@tripep.se Anders Vahlne, Head of Research Tel: +46 (0)8 5858 1313, mobile: +46 (0)70 928 05 28 e-mail: anders.vahlne@labmed.ki.se

Documents & Links